S1PR4 and colitis: Olesch et al. [103] found that the ablation of the immune cell-specific receptor S1PR4, which leads to increased CD8+ T cell abundance, delays tumor development and increases treatment success in murine models of breast carcinoma and colitis-associated colorectal cancer.